Bicycle Therapeutics reports Q3 EPS (74c), consensus (78c)

Reports Q3 revenue $2.68M, consensus $6.84M …Cash and cash equivalents of $890.9 million as of September 30, 2024, excluding $31.7 million UK R&D tax credit received in October 2024; expected financial runway into 2H 2027…”In the third quarter, we continued to make significant advancements across our business and pipeline. At ESMO, we reported updated data for our clinical-stage molecules, further supporting their promising monotherapy response rates and differentiated safety profiles. Additionally, last week we shared exciting first human imaging data for our first radiopharmaceuticals molecule, validating the potential of MT1-MMP as a novel cancer target and providing important information on the ability of our Bicycle molecules to deliver radioisotopes to the tumor,” said Kevin Lee, Ph.D., CEO of Bicycle Therapeutics (BCYC). “Altogether, we believe these data demonstrate the power and broad capabilities of our Bicycle technology platform, and we look forward to providing additional updates later this year.”